Literature DB >> 11765290

Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.

R L Findling1, E J Short, M J Manos.   

Abstract

OBJECTIVES: To examine the relationship between age and short-term clinical response to psychostimulant treatment in youths with attention-deficit/hyperactivity disorder (ADHD) and to examine whether weight-corrected doses of optimized psychostimulant therapy varied as a function of patient age.
METHOD: One hundred seventy-seven patients were treated with either methylphenidate (MPH) or Adderall (ADL). Sixty-six youths received ADL and 111 patients were treated with MPH. All youths were evaluated at baseline and after receiving a week of treatment at each blinded, randomized dose level (placebo, 5, 10, or 15 mg). A "best dose" for each patient was assigned before the medication blind was broken. Behavioral ratings by both teachers and parents were examined for dose and medication effects.
RESULTS: The medications had similar efficacy in children and teenagers. Older youths, however, benefited from a smaller weight-adjusted dose of medication than did the younger children. Similar efficacy was observed between the medications.
CONCLUSIONS: These data suggest that psychostimulants are equally effective in treating children and adolescents with ADHD. Adolescents with ADHD may not necessarily require more medication than younger children to achieve a similar therapeutic response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11765290     DOI: 10.1097/00004583-200112000-00015

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  6 in total

1.  The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents.

Authors:  Guilherme Polanczyk; Stephen V Faraone; Claiton H D Bau; Marcelo M Victor; Katja Becker; Reta Pelz; Jan K Buitelaar; Barbara Franke; Sandra Kooij; Emma van der Meulen; Keun-Ah Cheon; Eric Mick; Diane Purper-Ouakil; Philip Gorwood; Mark A Stein; Edwin H Cook; Luis Augusto Rohde
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

Review 2.  Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?

Authors:  Josephine Elia; Victoria L Vetter
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 3.  Pharmacological management of attention-deficit hyperactivity disorder in adolescents: special considerations.

Authors:  Philip Hazell
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Childhood ADHD symptoms and risk for cigarette smoking during adolescence: School adjustment as a potential mediator.

Authors:  Kate Flory; Patrick S Malone; Dorian A Lamis
Journal:  Psychol Addict Behav       Date:  2011-06

5.  Adderall-induced Trichotillomania: A Case Report.

Authors:  Chiranjir Narine; Sajjad R Sarwar; Theodor B Rais
Journal:  Innov Clin Neurosci       Date:  2013-07

Review 6.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.